We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Siemens Increases Patient Access to Alzheimer’s Biomarker
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Siemens Increases Patient Access to Alzheimer’s Biomarker
BusinessNewsTechnology

Siemens Increases Patient Access to Alzheimer’s Biomarker

Steve Goldstein
Steve Goldstein
Share
4 Min Read
Alzheimer's biomarker
SHARE

Alzheimer's biomarkerAnticipating the onward march of aging Americans who will suffer from Alzheimer’s disease, Siemens’ PETNET Solutions has increased patient access to Eli Lilly and Company’s Amyvid biomarker (Florbetapir F 18 injection) by expanding manufacturing and distribution to a total of 20 metropolitan areas nationwide.

Alzheimer's biomarkerAnticipating the onward march of aging Americans who will suffer from Alzheimer’s disease, Siemens’ PETNET Solutions has increased patient access to Eli Lilly and Company’s Amyvid biomarker (Florbetapir F 18 injection) by expanding manufacturing and distribution to a total of 20 metropolitan areas nationwide. Among the new areas are Denver: Raleigh, N.C.; Boston,; Minneapolis; Hackensack, N.J.; Los Angeles, Fort Lauderdale, Fla. and Cleveland.

Siemens anticipates ultimately expanding to 24 U.S. sites and has already contracted for a production site near London and expects to add four more European sites. I stopped by the Siemens booth at the Vancouver Convention Center during the 2013 annual meeting of the Society of Nuclear Medicine and Molecular Imaging to talk about this with Edgar Alvarez, senior manager for Siemens’ PETNET marketing.

“We’re now capturing about 90 percent of the Alzheimer’s population at these 20 sites and we’re waiting for four more sites to come on line pending FDA approval,” said Alvarez. He explained that they map the prevalence of Alzheimer’s disease around the country and use that map to guide the siting of their production facilities. “We want to increase access where it’s needed, so that’s our strategy to build a network,” he said.  The reason for building sites close to where patients are, he explained, “is that there’s a limited time window to get the radioactive biomarker to the customer.” If the travel distance is too great then the injection begins to lose its optimal radiation level.

More Read

end-of-life decisions
Person-Centered HealthCare: Empowered Patients, Empowered Care
How Telehealth and 5G are Transforming Healthcare?
Hospital Marketing: Medicare Payments Collide with Delivery System Reform
1P-LSD Shapes the Future of Medical Research
Marketing When Your Waiting Room Is Full

In fact, said Alvarez, the syringe with the injection is calibrated per patient per exam time to get the exact amount of radioactivity. “And we try to get the dose delivered precisely when it’s needed for the patient,” he said. Alvarez said they provide a “radioactive buffer” in the event the procedure is delayed.

The sites have been built in phases to adjust to the changing Alzheimer’s population. There are now 5.2 million Americans suffering from the disease, according to the American Alzheimer’s Association. Someone is added to that total every 68 seconds, and the projection is as many as 16 million Americans living with the disease by 2030.Typically, Alzheimer’s has been difficult to diagnose, with certainty often not available until autopsy.  Last year, at the SNMMI annual meeting in Miami, Siemens demonstrated its integrated amyloid imaging solution, a combination of hardware and software as well as a reliable imaging biomarker — Amyvid. Amyloids are proteins that create plaque in the brain, inhibiting neurons, in much the same way that arterial plaque causes heart disease.

The first element of the solution is the Biograph mCT positron emission tomography/computer tomography (PET-CT) system. What’s interesting about this machine is that it can reportedly differentiate between gray and white brain matter with higher resolution that can not only visualize the uptake of amyloids but quantify the uptake. The system is considered revolutionary by some because it offers a PET visualization of amyloids and supports early insights into the diagnosis of Alzheimer’s.

(biomarker / shutterstock)

TAGGED:SiemensSNMMI13
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare volunteer communication as a two-way, coordinator-supported process for confirming schedu
How to Manage Volunteer Communication in Healthcare: 5 Tactical Steps and Software Options
Global Healthcare
November 18, 2026
The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026

You Might also Like

Why Hospitals Need Content Management to Maximize Patient Experience

May 25, 2013
Image
News

Top 5 Posts on HealthWorks Collective [August]

September 1, 2016
health technology stocks
Technology

Everything You Need to Know About Investing in Health Technology Stocks

May 23, 2021
Healthcare Quality
Business

The Quest for Healthcare Quality Part II: Patient Perspectives

June 25, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?